Thomas Aparicio

13.5k citations
257 papers · 6.7k · 2 hit papers · h-index 41

Impact in

    • Gastrointestinal Tumor Research and Treatment
  • Oncology top 0.5%
    • Pancreatic and Hepatic Oncology Research
    • Colorectal Cancer Treatments and Studies
    • Lung Cancer Research Studies

Papers in

    • Colorectal Cancer Treatments and Studies 81
    • Pancreatic and Hepatic Oncology Research 21
    • Cancer Treatment and Pharmacology 20
    • Colorectal Cancer Surgical Treatments 17
    • Gastric Cancer Management and Outcomes 55
    • Lung Cancer Treatments and Mutations 16

Thomas Aparicio

240 papers receiving 6.5k citations

Thomas Aparicio's Hit Papers

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study 2022 · 239 citations
2390+6+12Years since publication100200300400500

Peers

Thomas Aparicio
Comparison fields: 5 of 116
  • Gastroenterology 995
  • Oncology 2.8k
  • Geriatrics and Gerontology 262
  • Cancer Research 631
  • Pulmonary and Respiratory Medicine 1.3k
Replace Giuseppe Aprile with:
Giuseppe Aprile Italy
Thierry Lecomte France
Naureen Starling United Kingdom
Kazuhiro Yoshida Japan
Stephen Falk United Kingdom
Fumio Konishi Japan
Benjamin Tan United States
Masanori Terashima Japan
Hiroki Yamaue Japan
Romain Coriat France
Thomas Aparicio relative to Giuseppe Aprile Italy Giuseppe Aprile's profile →
Citations per field
00.5×3.4×
Giuseppe Aprile · 1×
Citations per year

Countries citing papers authored by Thomas Aparicio

Since Specialization
Citations

This map shows the geographic impact of Thomas Aparicio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Aparicio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Aparicio more than expected).

Fields of papers citing papers by Thomas Aparicio

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Aparicio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Aparicio. The network helps show where Thomas Aparicio may publish in the future.

Co-authors

The 25 scholars most cited alongside Thomas Aparicio, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Thomas Aparicio Line = papers co-authored together Thomas Aparicio links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 257 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study
Hit paper breakdown →
2008507
2 1999369
3 2010246
4
Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study
Hit paper breakdown →
2022239
5 2019206
6 2013201
7 2014171
8 2001162
9 2013155
10 2017147
11 2011135
12 2004127
13 2009127
14 2004121
15 2012113
16 2010103
17 200594
18 201288
19 200885
20 201184

About Thomas Aparicio

Thomas Aparicio is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Gastroenterology and Pathology and Forensic Medicine, having authored 257 papers that have together received 6.7k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (81 papers), Gastric Cancer Management and Outcomes (55 papers), Gastrointestinal Tumor Research and Treatment (31 papers), Genetic factors in colorectal cancer (26 papers), Pancreatic and Hepatic Oncology Research (21 papers), Cancer Treatment and Pharmacology (20 papers), Colorectal Cancer Surgical Treatments (17 papers) and Lung Cancer Treatments and Mutations (16 papers). The work is most often cited by research in Gastroenterology (995 citations), Oncology (2.8k citations), Geriatrics and Gerontology (262 citations), Cancer Research (631 citations) and Pulmonary and Respiratory Medicine (1.3k citations). Thomas Aparicio has collaborated with scholars based in France, Germany and United States. Frequent co-authors include P. Rougier, Olivier Bouché, Aziz Zaanan, Michel Ducreux, Julien Taı̈eb, Emmanuel Mitry, Thierry Lecomte, Laurent Bedenne, Pierre Laurent‐Puig and Iradj Sobhani. Their work appears in journals such as Journal of Clinical Oncology, Digestive and Liver Disease, Annals of Oncology, European Journal of Cancer and Cancers.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact